Welcome to our dedicated page for ZEO ScientifiX SEC filings (Ticker: zeox), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can be a maze of scientific jargon and FDA risk factors—especially when they cover regenerative therapies like Zofin™ and PPX™. If you have ever searched “How do I find ZEO ScientifiX insider trading Form 4 transactions” only to dig through hundreds of pages, you know the challenge. ZEOX disclosures contain trial protocols, cash-runway projections and patent updates that are easy to miss.
Stock Titan turns that problem into a fast answer. Our AI reads every ZEOX submission the moment it hits EDGAR, then delivers plain-English takeaways. Need the “ZEO ScientifiX quarterly earnings report 10-Q filing” or want “ZEO ScientifiX Form 4 insider transactions real-time”? They appear in a single dashboard, alongside trend charts and peer comparisons. You can skim AI-powered summaries that make “ZEO ScientifiX SEC filings explained simply,” drill into “ZEO ScientifiX earnings report filing analysis,” or set alerts for material events when a “ZEO ScientifiX 8-K material events explained” post arrives.
Beyond speed, our coverage links each document to what matters in a biotech balance sheet: R&D expense swings, Phase II enrollment updates, and deferred tax assets. Track “understanding ZEO ScientifiX SEC documents with AI” by exploring sections that map trial milestones to funding needs. Follow “ZEO ScientifiX executive stock transactions Form 4,” review a “ZEO ScientifiX annual report 10-K simplified,” and study the “ZEO ScientifiX proxy statement executive compensation.” Every form type—10-K, 10-Q, 8-K, S-1—is updated in real time, giving biotech investors the clarity they need to evaluate this innovative regenerative-medicine contender.
Zeo ScientifiX, Inc. (ZEOX) filed a Form 10-Q showing constrained liquidity and a continuing operations focus on clinical and commercial support. The company reported $4,706,000 for the nine months ended July 31, 2025, used $335,000 of cash in operating activities in that period, and had a stockholders’ deficit of $2,314,000 at July 31, 2025. The balance sheet shows multiple finance leases entered into in June 2025 for equipment (one with 60 monthly payments of $1,600 at 2.7% and one with 36 monthly payments of $500 at 8.0%), and a recent asset purchase of BIO assets with a $200,000 purchase price largely allocated to inventory.
Capital structure items include $725,000 of convertible debt (convertible into up to 120,834 shares), significant stock-based compensation and warrant grants (including grants with a $1,428,000 fair value for warrants), and 263,333 unvested restricted shares (178,333 unissued). Revenue concentration is notable, with single customers representing double-digit percentages of revenues in multiple periods. The filing discloses commissions earned under a Sales Agreement ($62,000 for nine months ended July 31, 2025) and related-party product sales to an MSO tied to the Chief Medical Officer.
FAQ
What is the current stock price of ZEO ScientifiX (zeox)?
What is the market cap of ZEO ScientifiX (zeox)?
